Pinealon

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator family, researched for pineal-gland-targeted neuroprotection, cognitive preservation, and melatonin pathway regulation. It is one of the synthesized (rather than tissue-extracted) Khavinson compounds, with a defined three-amino-acid sequence. Pinealon is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.

What is Pinealon and how does the pineal-targeted bioregulatory mechanism work?

Pinealon is a synthetic Glu-Asp-Arg tripeptide proposed to enter pineal-cell nuclei and modulate gene expression in pathways related to melatonin synthesis, antioxidant response, and neuroprotection. The Khavinson framework treats Pinealon as the tripeptide complement to the tetrapeptide Epithalon, with both targeting pineal tissue but through proposed-distinct sequence-specific gene-expression effects. Preclinical work has reported effects on oxidative stress response, neuronal apoptosis pathways, and cognitive performance markers in rodent models.

Source: Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes, Khavinson V. et al. (optional, non-blocking follow-up: confirm full list), Rejuvenation Research, 2011 · Evidence level: preclinical (rodent neuroprotection, oxidative stress); Khavinson-group human research; independent replication limited

What does the research show for Pinealon?

Preclinical rodent studies from the Khavinson group have reported neuroprotective effects against oxidative stress, improved cognitive performance markers in aging rodents, and effects on pineal gene expression related to melatonin synthesis. Human research has been conducted in Russian clinical contexts but is not characterized at FDA-grade Phase 2/3 standards. The most-cited mechanistic study (Fedoreyeva et al., 2011, Biochemistry (Moscow)) reported nuclear entry of fluorescently-labeled short peptides — Pinealon among them — in cultured (HeLa) cells and sequence-specific interaction with DNA in vitro.

Source: Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA, Fedoreyeva L.I., Kireev I.I., Khavinson V.Kh., Vanyushin B.F. (optional, non-blocking follow-up: confirm full list), Biochemistry (Moscow), 2011 · Evidence level: preclinical (rodent and cell culture); Khavinson-group human research; FDA-grade Phase 2/3 not conducted

How does Pinealon compare to Epithalon and other Khavinson bioregulators?

Pinealon and Epithalon are the two Khavinson bioregulators specifically targeting pineal gland tissue — Pinealon is a tripeptide proposed for neuroprotection and melatonin pathway support, Epithalon is a tetrapeptide proposed for telomerase activation and broader aging effects. They are often used together in Khavinson-protocol research.

What are the documented side effects of Pinealon?

Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The Khavinson bioregulator class as a whole has a favorable safety profile in available data, attributed to the short peptide length and proposed nuclear-entry mechanism that does not engage surface receptor cascades. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards.

Evidence level: preclinical safety; human long-term unestablished at Western clinical standards

What is the regulatory status of Pinealon?

Pinealon is not approved by the FDA, EMA, or any major Western regulator as of August 2026. Pinealon is not on the FDA's active Section 503A/503B Category-2 bulk-substances list, and it was not among the peptides the FDA addressed in its April 2026 Category-2 actions or the July 2026 Pharmacy Compounding Advisory Committee meeting — no U.S. compounding pathway applies to it. It is used in Russian clinical and research contexts as part of Khavinson-framework protocols but does not have a defined Western regulatory pathway. The FDA's broader position on bioregulator peptides has been in flux during 2024–2026 — see FDA peptide regulation 2025–2026 timeline.

Source: FDA 503A bulk drug substances (Category 1/2) page

Why does Pinealon vendor verification matter?

Pinealon's short tripeptide structure makes synthesis straightforward and broadly available across research-grade vendors, but identity and purity verification still matters — related Khavinson tripeptides can be mislabeled, and the small molecular weight (418.4 Da for the free tripeptide) requires mass spectrometry confirmation to distinguish from other short peptides. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.

Source: Pinealon (Glu-Asp-Arg / EDR) — compound identity, PubChem (NCBI), PubChem, 2026

How does Peptigrity verify Pinealon vendors?

Peptigrity collects independent third-party Certificates of Analysis for Pinealon from shops' official channels and verifies each for authenticity before publishing. Because shops choose which COAs to publish, results reflect the batches shops have made public rather than every production batch — a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. Tests in the database come from independent labs such as Janoshik Analytical, Freedom Diagnostics, and Chromate. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.

Frequently asked questions

What does Pinealon do?

Pinealon is proposed to act on pineal gland tissue through epigenetic gene-expression modulation, with preclinical research focused on neuroprotection, oxidative stress reduction, and cognitive performance markers. Effects in humans at Western Phase 2/3 standards are not characterized; the evidence base comes from the Khavinson research group and Russian clinical contexts.

How does Pinealon differ from Epithalon?

Both target pineal gland tissue but have different sequences (Pinealon is a tripeptide Glu-Asp-Arg; Epithalon is a tetrapeptide Ala-Glu-Asp-Gly) and different proposed primary effects — Pinealon for neuroprotection and cognitive markers, Epithalon for telomerase activation and broader anti-aging effects. They are often used together in Khavinson-protocol research.

Is Pinealon legal to purchase?

Pinealon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.

Will Pinealon be FDA-approved?

No active FDA approval pathway exists for Pinealon as of August 2026. Bioregulator peptides are not currently being advanced through FDA clinical development by any pharmaceutical sponsor.

How can I verify a Pinealon vendor is selling real product?

Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW 418.4 Da, free tripeptide). COA interpretation in red flags in peptide certificates of analysis.

Does Peptigrity recommend a Pinealon dose?

No. Pinealon is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Khavinson-protocol dosing varies by research context. Anyone considering use should consult a licensed physician.

This section is for educational and informational purposes only and does not constitute medical advice. Pinealon is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.